Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia

Drusano G. L.

Source: Eur Respir Rev 2007; 16: 45-49
Journal Issue: August 2007 - 16 (103)
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Drusano G. L.. Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia. Eur Respir Rev 2007; 16: 45-49

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007



Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011



Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004

Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Source: Eur Respir J 2007; 30: 307-313
Year: 2007



Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002



Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010



The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008

Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003



Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia
Source: Eur Respir J 2007; 30: 1234-1235
Year: 2007


Aerosolised treatment for VAP
Source: Eur Respir Mon 2011; 53: 54-65
Year: 2011


Optimising the duration of antibiotic therapy for ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 40-44
Year: 2007



New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011


Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Source: Eur Respir J 2006; 27: 158-164
Year: 2006



Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury
Source: Eur Respir J 2016; 47: 1219-1228
Year: 2016



VAP: approach to therapy
Source: Eur Respir Mon 2011; 53: 36-47
Year: 2011


Cost-effective antibiotic management of community acquired pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198
Year: 2004

Impact of guidelines on HAP and VAP outcomes
Source: Eur Respir Mon 2011; 53: 66-73
Year: 2011


Nebulised colistin for ventilator-associated pneumonia prevention
Source: Eur Respir J 2015; 46: 1732-1739
Year: 2015



Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008


Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007